|Description||Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Now it is in Phase II trials for the treatment of Graft-versus-host disease; Non-small cell lung cancer.|
|Solubility||DMSO: ＞ 35 mg/Ml|
|Application||Graft-versus-host disease; Non-small cell lung cancer|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||AstraZeneca; Incyte Corporation|
The hydrochloride salt form of NS-018 which is a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tum...
WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...
Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...
AC410 is a Janus kinase 2 (JAK2) inhibitor with Kd of 0.18 nM. AC410 is selective for JAK2 and Kd is 2.5 nM for JAK1 and 5nM for JAK3. Phase I for the treatment...
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...
CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-...
SD 1008 is a JAK2/STAT3 signaling pathway inhibitor that inhibits activation of STAT3, JAK2 and Src. SD 1008 induces apoptosis in cell lines expressing constitu...
Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...
NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2...
CEP-33779 is a highly selective, orally active, small-molecule inhibitor of JAK2. CEP-33779 induced regression of established colorectal tumors, reduced angioge...
ZM 39923 hydrochloride
ZM 39923 hydrochloride is a potent and selective inhibitor of Janus tyrosine kinase 3 (JAK3) (pIC50 = 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4, re...
ZM 39923 inhibits Janus kinase (IC50=10 nM).
Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhib...
BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...
Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It ...
BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and oth...
Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).